Evolving Treatment Strategies in Small Cell Lung Cancer

Centering discussion on several patient scenarios, expert panelists review recent clinical data and consider how it has impacted their management of patients with small cell lung cancer (SCLC).

EP. 1: Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer

June 26th 2023

Expert oncologists provide an overview of the landscape surrounding small-cell lung cancer and highlight the importance of early referral and diagnosis for overall patient outcomes.

EP. 2: Impact of Disease Staging on Prognosis and Treatment in SCLC

June 26th 2023

Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.

EP. 3: Evolving Role of Biomarkers in SCLC

July 3rd 2023

Faculty discuss the evolving role of molecular markers in small-cell lung cancer and the need for future research to identify improved biomarkers for targeted treatment options.

EP. 4: Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases

July 3rd 2023

A panel of expert oncologists present the case of a 68-year-old man with newly diagnosed, extensive stage small-cell lung cancer and brain metastases, who is treated with carboplatin, etoposide, and durvalumab, and provide their initial impressions.

EP. 5: Expert Insights on First-line Treatment Strategies in SCLC

July 10th 2023

An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.

EP. 6: CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes

July 10th 2023

Expert oncologists discuss long-term data updates from the CASPIAN trial and the associated implications on clinical practice.

EP. 7: Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC

July 17th 2023

Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.

EP. 8: ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC

July 17th 2023

Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.

EP. 9: Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

July 24th 2023

Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.

Evolving Treatment Strategies in Small Cell Lung Cancer

EP. 1: Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer

EP. 2: Impact of Disease Staging on Prognosis and Treatment in SCLC

EP. 3: Evolving Role of Biomarkers in SCLC

EP. 4: Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases

EP. 5: Expert Insights on First-line Treatment Strategies in SCLC

EP. 6: CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes

EP. 7: Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC

EP. 8: ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC

EP. 9: Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%

EP. 10: Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC

EP. 11: Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

EP. 12: Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond

EP. 13: LAGOON and IMFORTE Trials: Data Updates and Expert Insights

EP. 14: 2L Dosing Considerations and Management Strategies for SCLC

EP. 15: Novel Treatment Approaches for SCLC and Future Perspectives